Findings of Research Misconduct, 8148-8149 [2013-02487]
Download as PDF
<![CDATA[
8148
Federal Register / Vol. 78, No. 24 / Tuesday, February 5, 2013 / Notices
A copy of the charter for the 2015
DGAC can be obtained from the
designated contacts. A copy of the
charter also will be made available on
the FACA database after the document
is filed with the appropriate
Congressional committees and the
Library of Congress. The FACA database
is a shared management system that is
maintained by the GSA Committee
Management Secretariat. The Web site
for the FACA database is https://fido.gov/
facadatabase/.
Dated: January 30, 2013.
Howard K. Koh,
Assistant Secretary for Health.
[FR Doc. 2013–02502 Filed 2–4–13; 8:45 am]
BILLING CODE 4150–32–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
Bryan William Doreian, Ph.D., Case
Western Reserve University: Based on
the admission of the Respondent, ORI
found that Dr. Bryan William Doreian,
former postdoctoral fellow, Department
of Dermatology, Case Western Reserve
University (CWRU), engaged in research
misconduct in research supported by
National Heart, Lung, and Blood
Institute (NHLBI), National Institutes of
Health (NIH), grant T32 HL07887 and
National Institute of Neurological
Disorders and Stroke (NINDS), NIH,
grant R01 NS052123.
ORI found that the Respondent
engaged in research misconduct by
falsifying data that were included in:
• Doreian, B.W. ‘‘Molecular
Regulation of the Exocytic Mode in
Adrenal Chromaffin Cells.’’ Submitted
in partial fulfillment of the requirements
for the degree of Doctor of Philosophy,
August 2009; hereafter referred to as the
‘‘Dissertation.’’
• Doreian, B.W., Fulop, T.G.,
Meklemburg, R.L., Smith, C.B. ‘‘Cortical
F-actin, the exocytic mode, and
neuropeptide release in mouse
chromaffin cells is regulated by
myristoylated alanine-rich C-kinase
substrate and myosin II.’’ Mol Biol Cell.
20(13):3142–54, 2009 Jul; hereafter
referred to as the ‘‘Mol Biol Cell paper.’’
• Doreian, B.W., Rosenjack, J., Galle,
P.S., Hansen, M.B., Cathcart, M.K.,
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:18 Feb 04, 2013
Jkt 229001
Silverstein, R.L., McCormick, T.S.,
Cooper, K.D., Lu, K.Q. ‘‘Hyperinflammation and tissue destruction
mediated by PPAR-g activation of
macrophages in IL–6 deficiency.’’
Manuscript prepared for submission to
Nature Medicine; hereafter referred to as
the ‘‘Nature Medicine manuscript.’’
As a result of the Respondent’s
admission, the Respondent will request
that the following paper be retracted:
Mol Biol Cell. 20(13):3142–54, 2009 Jul.
ORI finds that Respondent falsified
numerical values in the Mol Biol Cell
paper, the submitted Nature Medicine
manuscript, and the Dissertation by
altering the number of samples or the
experimental results to improve the
statistical results. Specifically, ORI finds
that Respondent:
1. Falsified the quantification of
immunofluorescence for the ratio of
phosphorylated to unphosphorylated
MARCKS protein in response to
different stimuli in Figure 2 of the Mol
Biol Cell paper and in Figure 12 of the
Dissertation by falsifying the sample
number as n=15.
2. Falsified the quantification of
immunofluorescence for filamentous
actin in response to different stimuli in
Figure 3 of the Mol Biol Cell paper and
in Figure 13 of the Dissertation by
falsifying the sample number as n=15.
3. Falsified the quantification for the
effect of blebbistatin on catecholamine
release as determined by patch clamp
analysis in Figure 22 of the Dissertation
by stating that 14 cells had been assayed
when only 8 cells had been assayed.
4. Falsified the Pearson’s crosscorrelation analysis in Figure 7 of the
Mol Biol Cell paper and in Figure 25 of
the Dissertation, used to calculate the
degree of spatial correlation between
pan-chromogranin A/B (CgA/B) and the
endosomal membrane, by stating that 20
or more cells had been tested for each
condition when only 9–18 cells had
been tested for each condition.
5. Falsified RT–PCR values for iNOS
and TNF-alpha expression recorded on
spreadsheets and presented in Figures
5e and 5f of the Nature Medicine
manuscript showing the effect of hyperinflammatory macrophage generation on
tissue destruction, by falsifying the
numeric values to fit the hypothesis of
the manuscript.
6. Falsified ELISA graphs for the
concentration of TNF-a in the aAB IL–
6 mice and their controls in Figure 6j of
the Nature Medicine manuscript
showing the effect of rosiglitazone
treatment in the mice, by multiplying
the experimental values by 100 to match
the magnitude of the values presented
in Figures 21, 6h, and 6i of the Nature
Medicine manuscript.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
7. Falsified the RT–PCR results
presented in the Nature Medicine
manuscript for quantification of iNOS
and TNF-a RNA expression by claiming
that the results represent the rmean of
three identical experiments when the
three experiments were normalized
differently to yield the desired result.
Specifically, false results were
presented for peritoneal macrophages
treated in vivo with rosiglitazone and/
or inhibitors of PPARg signaling Figures
1g, 1h, and 1i, and for iNOS RNA
expresssion in IL6-/- macrophages
treated in vitro with either SOCS3
antisense oligonucleotides in Figure 2g
or the STAT3 decoy in Figure 2j.
Dr. Doreian has entered into a
Voluntary Settlement Agreement and
has voluntarily agreed for a period of
three (3) years, beginning on January 15,
2013:
(1) To have his research supervised;
Respondent agreed that prior to the
submission of an application for U.S.
Public Health Service (PHS) support for
a research project on which his
participation is proposed and prior to
his participation in any capacity on
PHS-supported research, Respondent
shall ensure that a plan for supervision
of his duties is submitted to ORI for
approval; the supervision plan must be
designed to ensure the scientific
integrity of his research contribution; he
agreed that he shall not participate in
any PHS-supported research until such
a supervision plan is submitted to and
approved by ORI; Respondent agreed to
maintain responsibility for compliance
with the agreed upon supervision plan;
(2) That any institution employing
him shall submit, in conjunction with
each application for PHS funds, or
report, manuscript, or abstract involving
PHS-supported research in which
Respondent is involved, a certification
to ORI that the data provided by
Respondent are based on actual
experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract;
(3) To exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant; and
(4) To request that the following paper
be retracted: Mol Biol Cell. 20(13):3142–
54, 2009 Jul.
FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
E:\FR\FM\05FEN1.SGM
05FEN1
8149
Federal Register / Vol. 78, No. 24 / Tuesday, February 5, 2013 / Notices
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.
David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2013–02487 Filed 2–4–13; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Extension of a Currently Approved
Information Collection; Comment
Request
Proposed Projects
Title: Cross-Site Evaluation of
Children’s Bureau’s Child Welfare
Technical Assistance Implementation
Centers and National Child Welfare
Resource Centers.
OMB No.: 0970–0377.
Background and Brief Description:
The Cross-Site Evaluation of the Child
Welfare Implementation Centers (ICs)
and National Resource Centers (NRCs) is
sponsored by the Children’s Bureau,
Administration for Children and
Families, of the U.S. Department of
Health and Human Services and
involves the conduct of a multi-year
cross-site evaluation that examines the
service provision of the ICs’ and NRCs’
and the relation of their training and
technical assistance activities to
organizational and systems change in
State and Tribal child welfare systems.
Additionally, the evaluation examines
the degree to which networking,
collaboration, information sharing,
adherence to common principles, and
common messaging occurs across
members of the Children’s Bureau
Training and Technical Assistance (T/
TA) Network, which is designed to
improve child welfare systems and to
support States and Tribes in achieving
sustainable, systemic change that results
in greater safety, permanency, and wellbeing for children, youth, and families.
The Children’s Bureau desires to assess
the quality and effectiveness of the
technical assistance it supports, and
several of these programs and projects
are required to be evaluated, including
those funded under Section 105 of The
Child Abuse Prevention and Treatment
Act, as amended [42 U.S.C. 5106]. The
Children’s Bureau T/TA Network is
currently comprised of providers
funded entirely or partially by the
Children’s Bureau through grants,
contracts, and interagency agreements.
The cross-site evaluation uses a
mixed-method, longitudinal approach.
Data collection methods that already
have been employed are a longitudinal
telephone survey of State and Tribal
child welfare directors (or their
designees), a web-based survey of State
and Tribal T/TA recipients, and
aggregation of outputs from a web-based
technical assistance tracking system
(OneNet) that will continue to be used
by the ICs and NRCs. A web-based
survey also has been administered to
members of the T/TA Network to assess
their communication, coordination, and
how they function as part of the
Network. Data collected through these
instruments are being used by the
Children’s Bureau to evaluate the
technical assistance delivered to State,
local, Tribal, and other publicly
administered or publicly supported
child welfare agencies and family and
juvenile courts. Extension of the followup data collection instruments beyond
the June 30, 2013 expiration date is
necessary so that the Children’s Bureau
can assess the extent to which its T/TA
providers achieve their key objectives
and determine the outcomes of the T/
TA from the perspective of States and
Tribes, incorporating service utilization
data from OneNet into these analyses.
Respondents: Respondents to two of
the survey instruments will be State and
Tribal governments. Respondents to the
third survey will be private institutions,
including universities, not-for-profit
organizations, and private companies.
Private institutions, including
universities and not-for-profit
organizations will be respondents to the
forms in the OneNet tracking system.
ANNUAL BURDEN ESTIMATES
Number of
respondents
Instrument
Number of
responses per
respondent
Average burden
hours per
response
74
160
15
17
13
13
12
5
5
5
5
1
3
1
11.8
12.31
6.2
160
1.7
4.6
600
36
1.0
0.25
0.25
0.25
0.40
0.28
0.30
0.40
0.28
0.30
0.17
Estimated Total Annual Burden Hours: ..........................................
tkelley on DSK3SPTVN1PROD with NOTICES
Agency Results Survey .........................................................................
T/TA Activity Survey ..............................................................................
Web-Based Network Survey .................................................................
OneNet Form: General T/TA Event .......................................................
OneNet Form: T/TA Request ................................................................
OneNet Form: T/TA Assessment and Work Plan .................................
OneNet Form: T/TA Activity ..................................................................
OneNet Form: Implementation Project Application ...............................
OneNet Form: Implementation Project Assessment and Work Plan ....
OneNet Form: Implementation Project T/TA Activity ............................
OneNet Form: Implementation Project Monthly Report ........................
........................
............................
..........................
Overall, the estimated burden hours
have decreased by 284 hours from the
original submission (the estimated total
annual burden hours were 2135.12).
This difference is explained in part due
to plans for fewer Network member
organizations to complete subsequent
surveys. Additional data fields have
been added to four of the OneNet forms
at the request of respondents, and a few
questions on survey instruments have
VerDate Mar<15>2010
17:18 Feb 04, 2013
Jkt 229001
been removed or revised. These minor
changes did not increase the total
annual burden hours.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Administration, Office of Information
Services, 370 L’Enfant Promenade SW.,
Washington, DC 20447, Attn: ACF
Reports Clearance Officer. All requests
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Total annual
burden hours
74.00
120.00
3.75
50.00
64.00
22.568
576.00
3.4
6.44
900
30.60
1850.76
should be identified by the title of the
information collection. Email address:
infocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection information between 30 and
60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
E:\FR\FM\05FEN1.SGM
05FEN1
]]>Agencies
[Federal Register Volume 78, Number 24 (Tuesday, February 5, 2013)]
[Notices]
[Pages 8148-8149]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-02487]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
Bryan William Doreian, Ph.D., Case Western Reserve University:
Based on the admission of the Respondent, ORI found that Dr. Bryan
William Doreian, former postdoctoral fellow, Department of Dermatology,
Case Western Reserve University (CWRU), engaged in research misconduct
in research supported by National Heart, Lung, and Blood Institute
(NHLBI), National Institutes of Health (NIH), grant T32 HL07887 and
National Institute of Neurological Disorders and Stroke (NINDS), NIH,
grant R01 NS052123.
ORI found that the Respondent engaged in research misconduct by
falsifying data that were included in:
Doreian, B.W. ``Molecular Regulation of the Exocytic Mode
in Adrenal Chromaffin Cells.'' Submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy, August 2009;
hereafter referred to as the ``Dissertation.''
Doreian, B.W., Fulop, T.G., Meklemburg, R.L., Smith, C.B.
``Cortical F-actin, the exocytic mode, and neuropeptide release in
mouse chromaffin cells is regulated by myristoylated alanine-rich C-
kinase substrate and myosin II.'' Mol Biol Cell. 20(13):3142-54, 2009
Jul; hereafter referred to as the ``Mol Biol Cell paper.''
Doreian, B.W., Rosenjack, J., Galle, P.S., Hansen, M.B.,
Cathcart, M.K., Silverstein, R.L., McCormick, T.S., Cooper, K.D., Lu,
K.Q. ``Hyper-inflammation and tissue destruction mediated by PPAR-
[gamma] activation of macrophages in IL-6 deficiency.'' Manuscript
prepared for submission to Nature Medicine; hereafter referred to as
the ``Nature Medicine manuscript.''
As a result of the Respondent's admission, the Respondent will
request that the following paper be retracted: Mol Biol Cell.
20(13):3142-54, 2009 Jul.
ORI finds that Respondent falsified numerical values in the Mol
Biol Cell paper, the submitted Nature Medicine manuscript, and the
Dissertation by altering the number of samples or the experimental
results to improve the statistical results. Specifically, ORI finds
that Respondent:
1. Falsified the quantification of immunofluorescence for the ratio
of phosphorylated to unphosphorylated MARCKS protein in response to
different stimuli in Figure 2 of the Mol Biol Cell paper and in Figure
12 of the Dissertation by falsifying the sample number as n=15.
2. Falsified the quantification of immunofluorescence for
filamentous actin in response to different stimuli in Figure 3 of the
Mol Biol Cell paper and in Figure 13 of the Dissertation by falsifying
the sample number as n=15.
3. Falsified the quantification for the effect of blebbistatin on
catecholamine release as determined by patch clamp analysis in Figure
22 of the Dissertation by stating that 14 cells had been assayed when
only 8 cells had been assayed.
4. Falsified the Pearson's cross-correlation analysis in Figure 7
of the Mol Biol Cell paper and in Figure 25 of the Dissertation, used
to calculate the degree of spatial correlation between pan-chromogranin
A/B (CgA/B) and the endosomal membrane, by stating that 20 or more
cells had been tested for each condition when only 9-18 cells had been
tested for each condition.
5. Falsified RT-PCR values for iNOS and TNF-alpha expression
recorded on spreadsheets and presented in Figures 5e and 5f of the
Nature Medicine manuscript showing the effect of hyper-inflammatory
macrophage generation on tissue destruction, by falsifying the numeric
values to fit the hypothesis of the manuscript.
6. Falsified ELISA graphs for the concentration of TNF-[alpha] in
the aAB IL-6 mice and their controls in Figure 6j of the Nature
Medicine manuscript showing the effect of rosiglitazone treatment in
the mice, by multiplying the experimental values by 100 to match the
magnitude of the values presented in Figures 21, 6h, and 6i of the
Nature Medicine manuscript.
7. Falsified the RT-PCR results presented in the Nature Medicine
manuscript for quantification of iNOS and TNF-[alpha] RNA expression by
claiming that the results represent the rmean of three identical
experiments when the three experiments were normalized differently to
yield the desired result. Specifically, false results were presented
for peritoneal macrophages treated in vivo with rosiglitazone and/or
inhibitors of PPAR[gamma] signaling Figures 1g, 1h, and 1i, and for
iNOS RNA expresssion in IL6-/- macrophages treated in vitro
with either SOCS3 antisense oligonucleotides in Figure 2g or the STAT3
decoy in Figure 2j.
Dr. Doreian has entered into a Voluntary Settlement Agreement and
has voluntarily agreed for a period of three (3) years, beginning on
January 15, 2013:
(1) To have his research supervised; Respondent agreed that prior
to the submission of an application for U.S. Public Health Service
(PHS) support for a research project on which his participation is
proposed and prior to his participation in any capacity on PHS-
supported research, Respondent shall ensure that a plan for supervision
of his duties is submitted to ORI for approval; the supervision plan
must be designed to ensure the scientific integrity of his research
contribution; he agreed that he shall not participate in any PHS-
supported research until such a supervision plan is submitted to and
approved by ORI; Respondent agreed to maintain responsibility for
compliance with the agreed upon supervision plan;
(2) That any institution employing him shall submit, in conjunction
with each application for PHS funds, or report, manuscript, or abstract
involving PHS-supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived and that the
data, procedures, and methodology are accurately reported in the
application, report, manuscript, or abstract;
(3) To exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant; and
(4) To request that the following paper be retracted: Mol Biol
Cell. 20(13):3142-54, 2009 Jul.
FOR FURTHER INFORMATION CONTACT: Director, Office of Research
Integrity,
[[Page 8149]]
1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200.
David E. Wright,
Director, Office of Research Integrity.
[FR Doc. 2013-02487 Filed 2-4-13; 8:45 am]
BILLING CODE 4150-31-P
